MMF Dose Titration Decision

Context-Dependent Dosing Strategy

For patients with nephrotic syndrome, the initial dose is typically 1200 mg/m²/day divided twice daily, with a target duration of at least 12 months, as recommended by the Kidney International guidelines 1
The target MPA area under the curve is >50 µg·h/mL if therapeutic drug monitoring is available, according to the Kidney International guidelines 2
For patients with lupus nephritis, the early maintenance phase dose is 750-1000 mg twice daily, which translates to approximately 1.5-2g total daily dose, as recommended by the Kidney International guidelines 3
The total duration of immunosuppression for lupus nephritis should be ≥36 months, as recommended by the Kidney International guidelines 3

For patients with gastrointestinal intolerance, the dose can be switched to enteric-coated mycophenolic acid at 720-1080 mg twice daily, which is equivalent to MMF 1-1.5g twice daily, as recommended by the Journal of the American Academy of Dermatology guidelines 5, 6
Patients on MMF should have their CBC monitored every 2-3 months during therapy, as recommended by the Kidney International guidelines 2

The MPA blood levels should be checked if gastrointestinal intolerance develops or response is inadequate, and the target MPA AUC is 20-60 µg·h/mL for optimal efficacy and safety, as recommended by the Kidney International guidelines 2, 4
Patients on MMF should avoid concurrent use with antacids, cholestyramine, iron, or activated charcoal, as these inhibit absorption, as recommended by the Praxis Medical Insights guidelines 4

MMF should not be discontinued prematurely, as most patients relapse when stopped before 12 months, as recommended by the Kidney International guidelines 1, 2
The dose equivalence across formulations should not be assumed, as 360 mg sodium mycophenolate is equivalent to 500 mg MMF, as recommended by the Kidney International guidelines 2